November 4, 2024 01:46 PM EST
Pharma

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

Ayisha Sharma

News Reporter

De­spite strong third-quar­ter rev­enues, BioN­Tech has soft­ened its 2024 sales guid­ance in light of changes to Covid-19 vac­cine up­take, pric­ing and sea­son­al vari­a­tions.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times